...
首页> 外文期刊>Clinical and Experimental Metastasis >Matrix metalloproteinase inhibitor, MMI270 (CGS27023A) inhibited hematogenic metastasis of B16 melanoma cells in both experimental and spontaneous metastasis models
【24h】

Matrix metalloproteinase inhibitor, MMI270 (CGS27023A) inhibited hematogenic metastasis of B16 melanoma cells in both experimental and spontaneous metastasis models

机译:基质金属蛋白酶抑制剂MMI270(CGS27023A)在实验和自发转移模型中均抑制B16黑色素瘤细胞的生血转移

获取原文
获取原文并翻译 | 示例

摘要

Matrix metalloproteinases (MMP) have been implicated in several steps of tumor metastasis, such as invasion in the extracellular matrix, intravasation, extravasation, and growth in a distant organ site. Various synthetic MMP inhibitors have been reported to suppress tumor metastasis in animal models. However, there are few reports describing which steps in the metastasis process are most critical for inhibition by MMP inhibitors. In the experimental lung colonization model by i.v. injection of mouse B16-F10 melanoma cells, we found that the daily administration of MMI270 for 2 weeks significantly decreased the number of colonies in the lung compared with the control without affecting the size of colony. Micrometastasis was monitored day 7 post-inoculation by measuring the melanin content in the lung as well as by microscopic examination of the lung tissue sections. Even only twice administrations of MMI270 on the first day after tumor injection significantly inhibited micrometastasis in the lung. In the spontaneous metastasis model using B16-BL6 melanoma cells, lung metastasis was not affected by a continuous administration of MMI270 using a mini osmotic-pump. On the contrary, when mice were subjected to popliteal lymphadenectomy on day 7 after the cell inoculation in the footpad subdermis, the continuous administration of MMI270 significantly suppressed the lung metastasis. These results suggest that the tumor cell extravasation in the target organ is the most critical step where MMPs can play their significant role in the experimental metastasis, and that the lymphatic metastasis process is less susceptible to MMI270 than the hematogenic metastasis process in the spontaneous metastasis model.
机译:基质金属蛋白酶(MMP)已牵涉到肿瘤转移的多个步骤,例如细胞外基质的侵袭,血管内渗入,血管外渗以及在远处器官的生长。已经报道了多种合成的MMP抑制剂在动物模型中抑制肿瘤转移。但是,很少有报道描述转移过程中的哪些步骤对于MMP抑制剂的抑制最为关键。在实验性肺定植模型中注射小鼠B16-F10黑色素瘤细胞后,我们发现与对照组相比,每天服用MMI270 2周可显着减少肺中的菌落数量,而不会影响菌落的大小。接种后第7天通过测量肺中黑色素含量以及通过显微镜检查肺组织切片来监测微转移。肿瘤注射后的第一天,即使仅两次施用MMI270,也能显着抑制肺部微转移。在使用B16-BL6黑色素瘤细胞的自发转移模型中,使用微型渗透泵连续施用MMI270不会影响肺转移。相反,当在足垫皮下接种细胞后第7天对小鼠进行pop淋巴结清扫术时,连续给予MMI270可以显着抑制肺转移。这些结果表明,靶器官中的肿瘤细胞外渗是最重要的步骤,其中MMPs可在实验性转移中发挥重要作用,并且淋巴转移过程对MMI270的敏感性低于自发转移模型中的生血转移过程。 。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号